13/03/2006 (Agence Europe) - On 8 March, the European Medicines Agency (EMEA) published a set of guidelines on similar biological medicines. These guidelines, which will come into effect from 1st June 2006, define the criteria for gauging the “bio-similarity” of a generic medicines with the medicines of which they are a copy within the framework of the marketing authorisation procedure. EMEA is due to finalise an appendix on epoetin (recombinant human erythropoietin). The finalisation of...